Categories: News

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 17, 2021

CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that it will report financial results for the fourth quarter and full year 2020 and provide a corporate update on Wednesday, March 17, 2021, before the U.S. financial markets open. Management will discuss recent business and pipeline progress via a conference call and webcast at 8:00 a.m. ET on March 17.

Conference Call and Webcast Details:

US/Canada Toll Free:         833-398-1037

International:                       914-987-7735

Conference ID:                   7654828

Webcast:                            https://edge.media-server.com/mmc/p/kox4vezr

A replay of the webcast will be available approximately two hours following its conclusion and will be archived for 30 days following the event, accessible through the Events & Presentations page of the Investors + Media section of Praxis’ website at https://investors.praxismedicines.com/events-and-presentations.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis is applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological targets for severe pediatric epilepsies and more broadly for prevalent psychiatric diseases and neurologic disorders. Praxis has established a broad portfolio, including multiple disclosed programs across central nervous system disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates. For more information, please visit https://praxismedicines.com/.

CONTACT: Investor Contact:
Alex Kane
Praxis Precision Medicines
investors@praxismedicines.com
617-300-8481

Media Contact:
Ian Stone
Canale Communications
Ian.stone@canalecomm.com
619-849-5388

Staff

Recent Posts

The Doctor and The Athlete: Powerhouse Duo Disrupts Functional Beverage Market with Science-Backed “Happiness”

TAMPA, Fla., Feb. 2, 2026 /PRNewswire/ -- Happy Panda announces its official market launch with a…

4 hours ago

FUGO Precision 3D to Debut Revolutionary Centrifugal 3D Printing Technology with Live Demonstrations at LMT LAB DAY Chicago 2026

GARDENA, Calif., Feb. 2, 2026 /PRNewswire/ -- FUGO Precision 3D, developer of the world's first all-in-one…

4 hours ago

The Micro-Mechanics of Modern Oral Care

OXNARD, CA / ACCESS Newswire / February 2, 2026 / Quality Dental Services functions as…

7 hours ago

Dr. Shahrooz Yazdani Launches $6M Dental Practice Seminar Series to Help Owners Break Free from Burnout

Seminar offers step-by-step blueprint to grow your clinic, build passive income, and regain personal timeOTTAWA,…

10 hours ago

New Aura and UNC-Chapel Hill Study Finds One in Three Kids Have Accessed GenAI Apps

BOSTON, Feb. 2, 2026 /PRNewswire/ -- Aura, a leading AI-powered online safety platform for families,…

10 hours ago

‘Breathable’ Launches to Bring Hope and Humanity Back to Mental Health Care

New online network makes it simple, affordable and stigma-free to connect with licensed therapistsDETROIT, Feb.…

10 hours ago